Gamma Medica to Present at 2017 TPP Healthcare China Partnering Forum; in Conjunction with Biotech Showcase alongside JP Morgan Healthcare Conference

Forum aligns global investors and CEOs



Philip Croxford, President and CEO of Gamma
, will be presenting at 2017 TPP Healthcare China Forum
Cancer Diagnostics panel in conjunction with Biotech Showcase and
alongside the JP Morgan Healthcare Conference.


Editor’s Note: 1:1 interviews with Phil Croxford
are available on request.


Mr. Croxford will be discussing the clinical advantages and
advancements of Gamma Medica’s LumaGEM® Molecular
Breast Imaging (MBI) system, the company’s recent global expansion
and the future corporate strategy.



Panel Therapeutic Area: Women’s health: Monday, January 9, 2017;
10:00-11:00am PST

Panel Therapeutic Area: Cancer Diagnostics: Tuesday, January 10,
2017; 9:00-10:00am PST



Hilton Hotel, 55 Cyril Magnin St., San Francisco, CA 94102

Room Embarcadero, 3rd floor, Parc 55


Gamma Medica recently announced growth across the U.S., with
global expansion set for 2017 to bring its LumaGEM (MBI) system to
more leading health care facilities, giving women critical access
to accurate secondary breast cancer screenings options. This
growth coincides with the company’s educational Be
Certain campaign
, aiming to eliminate myths and raise
awareness about the facts on breast cancer detection and breast
health. Detecting breast cancer in dense breast tissue (affecting
50 percent of U.S. women) can be like looking for a snowflake in a
snowstorm, as dense tissue and cancerous growths both show white
on mammograms, as well as yield high
false positives
via other common screening methods. Molecular
imaging technology is
that, so every woman – no matter her breast density –
can get a fair and accurate diagnosis. Secondary screenings are an
important part of early breast cancer detection. MBI was
specifically designed to detect cancer in dense breast tissue.


About Gamma Medica, Inc.
Gamma Medica, Inc. is a women’s
health company focused on overcoming the limitations of anatomical
imaging experienced by mammography and other screening modalities in the
early detection of breast cancer, with women who have dense breast
tissue. The company’s LumaGEM® MBI system is the first commercially
available, FDA-cleared, fully solid-state digital imaging system
utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™)
technology for molecular breast imaging. With over 90 percent
sensitivity and specificity, LumaGEM MBI has been shown to significantly
improve cancer detection in women with dense breast tissue with fewer
false positives relative to anatomical imaging technologies, such as MRI
and whole breast ultrasound. For more information, visit,


Racepoint Global
Tara Kadioglu, 617-624-3239